SARS-CoV-2 Omicron variant in cancer patients: an insight into the vaccine booster debate
- PMID: 35109688
- PMCID: PMC8826832
- DOI: 10.2217/fon-2022-0024
SARS-CoV-2 Omicron variant in cancer patients: an insight into the vaccine booster debate
Comment on
-
COVID-19 mRNA booster vaccines elicit strong protection against SARS-CoV-2 Omicron variant in patients with cancer.Cancer Cell. 2022 Feb 14;40(2):117-119. doi: 10.1016/j.ccell.2021.12.014. Epub 2021 Dec 30. Cancer Cell. 2022. PMID: 34986328 Free PMC article. No abstract available.
References
-
- Petersen E, Ntoumi F, Hui DS et al. Emergence of new SARS-CoV-2 variant of concern Omicron (B.1.1.529) – highlights Africa's research capabilities, but exposes major knowledge gaps, inequities of vaccine distribution, inadequacies in global COVID-19 response and control efforts. Int. J. Infect. Dis. 114, 268–272 (2022). - PMC - PubMed
Publication types
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous